Ethanol Extracts of Dietary Herb, Alpinia nantoensis, Exhibit Anticancer Potential in Human Breast Cancer Cells. (August 2019)

• Record Type: Journal Article
• Authors: Kuo, Ching-Ying; Weng, Teng-Song; Kumar, K. J. Senthil; Tseng, Yen-Hsueh; Tung, Ta-Wei; Wang, Sheng-Yang; Wang, Hui-Chun
• Is Part Of: Integrative cancer therapies. Volume 18(2019)
• Publication Date: 2019-08
• Subjects: Alpinia nantoensis -- breast cancer -- metastasis -- PI3K/AKT -- Ras-ERK -- EGFR; Cancer -- Alternative treatment -- Periodicals; 616.99406
• DOI: 10.1177/1534735419866924
• Languages: English
• ISSNs: 1534-7354

Abstract

Recent advances in mammography screening, chemotherapy, and adjuvant treatment modalities have improved the survival rate of women with breast cancer. Nevertheless, the breast tumor with metastatic progression is still life-threatening. Indeed, combination therapy with Ras-ERK and PI3K inhibitors is clinically effective in malignant breast cancer treatment. Constituents from genus Alpinia plants have been implicated as potent anticancer agents in terms of their efficacy of inhibiting tumor cell metastasis. In this study, we tested the effects of ethanol extracts of Alpinia nantoensis (rhizome, stem, and leaf extracts) in cultured human breast cancer cells and particularly focused on the Ras-ERK and PI3K/AKT pathways. We found that the rhizome and leaf extracts from A nantoensis inhibited cell migration, invasion, and sphere formation in MCF-7 and MDA-MB-231 cells. The potency was extended with the inhibition of serum-induced PI3K/AKT and Ras-ERK activation and epidermal growth factor (EGF)-mediated EGFR activation in MDA-MB-231 cells. These results indicate that extracts of A nantoensis could inhibit signal transduction at least involved in EGFR as well as the PI3K/AKT and Ras-ERK pathways, which are crucial players of tumor cell migration and invasion. Our study strongly supports that the extracts of A nantoensis could be a novel botanical drug lead for the development of an antimetastatic agent for the treatment of human malignant breast cancer.